2020 Global Viral Clearance Market - Growth Rate, Opportunities, And Forecast

By Author: robert henric
Total Articles: 492
Comment this article

[159 Pages Report] The Global Viral Clearance Market is expected to reach USD 724.5 million, at a CAGR of 21.7%,

The key factors driving the growth of this market include growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and the high incidence and large economic burden of chronic diseases.

Research Methodology;

Top-down and bottom-up approaches were used to validate the size of the global viral clearance market and estimate the size of other dependent submarkets. Various secondary sources such as the International Society for Pharmaceutical Engineering, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), International Pharmaceutical Federation (FIP), International Diabetes Federation (IDF), European Federation of Biotechnology, International Rare Diseases Research Consortium (IRDiRC), Canadian Institutes of Health Research.

Objectives of the Study

To define, measure, and describe the global viral clearance market by application, method, ...
... end user, and region
To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
Browse 118 market data Tables and 33 Figures spread through 159 Pages and in-depth TOC – Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=62681197

By application, the recombinant proteins segment is expected to account for the largest share of the market in 2018

On the basis of application, the global market is segmented into four categories recombinant proteins, blood and blood products, vaccines, and other applications. In 2018, the recombinant proteins segment is expected to account for the largest share of the viral clearance market owing to the high potential of recombinant proteins to treat various diseases, fewer side effects, and shorter development time as compared to small molecules.

Furthermore, the regulatory requirement to demonstrate the capacity of the purification process to effectively clear infectious viruses during the manufacturing of recombinant proteins is also expected to support the growth of this market segment during the forecast period.

By end user, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the market in 2018

By end user, the viral clearance market is segmented into pharmaceutical & biotechnology companies, CROs, academic research institutes, and other end users. In 2018, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the global market. The large share of this segment can be attributed to the rapid expansion of the biopharmaceutical industry, growth in the number of research activities in life sciences, increasing R&D investments in drug development, and increasing number of drug launches.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=62681197

The North American region is expected to account for the largest share of the market in 2018. However, Asia Pacific is expected to witness the highest growth during the forecast period, owing to increase in generics development and manufacturing, surge in funding for medical research and the presence of a large number of CROs to provide preclinical and clinical research services in China, government initiatives to boost the use of generic drugs, increasing aging population in Japan, rise in pharmaceutical R&D expenditures in India, and the growing pharmaceutical manufacturing in Singapore and Malaysia.

The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France). These companies together accounted for 70.0% of the global viral clearance market in 2017. Other players together accounted for 30.0% of the market. These include Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).